


## PHARMACEUTICAL 2018



## NovaBay Pharmaceuticals Inc. Rank 267 of 342





## PHARMACEUTICAL 2018



## NovaBay Pharmaceuticals Inc. Rank 267 of 342

The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 157% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 79% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	8,995
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,979
Liabilities, Non-Current	215
Other Assets	613
Other Compr. Net Income	0
Other Expenses	16,599
Other Liabilities	2,291
Other Net Income	12
Other Revenues	18,230
Property and Equipment	471
Research and Development	410
Selling, General and Administrative Expense	8,636

Output Variable	Value in 1000 USD
Assets	10,079
Liabilities	7,485
Expenses	25,645
Revenues	18,230
Stockholders Equity	2,594
Net Income	-7,403
Comprehensive Net Income	-7,403
Economic Capital Ratio	-33%

